Genmab — Marts 2022
-
Børsen summary in Medwatch lol https://medwatch.dk/Medicinal___Biotek/article13878824.ece
-
Ja og problemet er trods alt, at det skal først skal kæmpe med Darzalex off patent og senere Darzalex faspro, så man skal godt nok være god. Chancerne er nok størst hvis det virker i nye indikationer eller i patienter der ikke længere responderer på daratumumab.
-
Vi ved at carvykti er super dyr og besværlig at arbejde med. Økonomisk får JNJ også mindre ud af den aftale end daraaftalen. Så hvis hexa38 kan komme på højde med det stof i effekt og bivirkninger er der ikke noget der taler for, at de ikke hopper på hexa38.
-
@Sukkeralf I was hoping for another hexabody mention in the BionTech presentation but there was none this time. The start of a hexabody trail with them would be nice support for the platform
-
SIFbody er åbenbart noget hexabody-agtigt, (multimerization). Mere potent end dara. Bedre til at aktivere CDC. Så en direkte konkurrent til superdara. https://aacrjournals.org/cancerres/article/79/13_Supplement/561/637257/Abstract-561-Discovery-of-a-potential-best-in
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind